Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Galen deal

GAL sold its U.K.-based pharmaceutical products sales and marketing business for £40 million

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE